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Say the word immunology, and most biologists will picture 
the responses enabled by somatic mutation of clonally 
distributed, highly variable antigen recognition structures. 
These receptors each interact with one particular species 
of oligopeptide displayed on one of many major histocom- 
patibility complex molecules to help trigger expansion of 
the lymphocyte clone bearing them. The resulting elimina- 
tion of the source of peptide is rewarded by capacity to 
respond faster to rechallenge with the same antigen. 
An immune system so elaborate has a high price. Its 
steepest cost is that first-response time--about 5-7 
days--is orders of magnitude longer than replication time 
for many microbes. Vertebrates have dealt with this di- 
lemma by engrafting the "adaptive" immune system upon 
one that Janeway (1989) called "innate," a phylogeneti- 
cally senior set of devices shared by many metazoans, 
including insects (Hoffmann et al., 1994) and plants (Ryan 
and Jagendorf, 1995). In contrast with adaptive immunity, 
the innate system detects a much smaller number of much 
less variable microbial molecular signatures, reading them 
with genetically stable recognition units predistributed on 
much larger numbers of cells. Geared for speed and oblivi- 
ous to evasion of antigen processing, the innate system 
scans for Gram-negative bacterial lipopolysaccharides, 
Gram-positive bacterial peptidoglycans and lipoteichoic 
acid-associated molecules, mycobacterial muramyl dipep- 
tides, mycolic acids and lipoglycans, fungal mannans and 
glucans, and bacterial CpG-rich nucleotides (Krieg et al., 
1995). Recognition mobilizes an armamentarium of burns, 
plugs, and poisons, often coupled with liquefaction of in- 
fected tissue. Not the least important function of the innate 
system is to jumpstart its adaptive counterpart (Janeway, 
1989). 
A Gene for Innate Immunity 
Although nonreliance on somatic mutation is the principle 
distinguishing feature of the innate immune response, 
polymorphisms will accumulate in its controlling genes. 
Some such mutations may confer (or lose) a phenotype, 
such as increased susceptibility (or decreased resistance) 
to infection. Such an allele could persist in inbred strains 
sheltered by unnaturally protective husbandry or could be 
fixed in the wild by conferral of or linkage with some advan- 
tageous, if inapparent, trait. Characterization of such ge- 
netic variants could be of enormous value. Their identifica- 
tion could lead to definition of the biochemical basis of 
an antimicrobial mechanism, as well as identification of 
patients with special needs for vaccination, other prophy- 
laxis, or intensive treatment. 
For these reasons, special notice attend ed the positional 
cloning of a gene on mouse chromosome 1 termed 
NRAMP1 (for natural resistance-associated macrophage 
protein 1) (Vidal et al., 1993). NRAMP1 was a candidate 
for the first cloned gene of the mammalian innate immune 
system whose alleles dictate susceptibility or resistance 
to infection. One set of microbes to which NRAMP1 was 
proposed to control innate responses includes Mycobacte- 
rium bovis variant bacille Calmette-Gu~rin (BCG), M. intra- 
cellulare, and M. lepraemurium. BCG is genetically almost 
identical to and often serves as a model for M. tuberculo- 
sis. The tuberculosis organism probably infects more of 
the world's human population (one third) and kills more 
people (nearly 3 million a year) than any other bacterial 
pathogen and has become the leading cause of death in 
people infected with human immunodeflciency virus. In 
human as in mouse, there is evidence for genetic control 
of susceptibility otuberculosis as well as to the other major 
mycobacterial disease, leprosy (see Vidal et al., 1993). 
Leishmania species, innate responses to which are con- 
trolled by a gene (Lsh) closely linked with or identical to 
Bcg, are agents of some of the world's most prevalent 
protozoal diseases. Another closely linked or identical 
gene, Ity, controls innate resistance to Salmonella typhi- 
murium. Recently, the case for NRAMPI's candidacy as 
the chromosome 1-situated mediator of resistance to all 
three organisms in mice--BCG, leishmania, and S. typhi- 
murium--was rendered definitive by the disruption of 
NRAMP1 in wild-type mice through homologous recombi- 
nation (Vidal et al., 1995). 
Hence, the following questions are of commanding inter- 
est. How does Nrampl work? Does its mechanism have 
anything to do with enhancing the antimicrobial potential 
of nitric oxide (NO), as suggested by its cloners (Vidal et 
al., 1993)? This minireview summarizes the reasons why 
NO is a plausible participant in Nrampl's actions, consid- 
ers cogent counterpoint, and offers speculative resolution 
to this unfinished story. 
NRAMP1 Controls Innate Resistance to 
Antigenically Dissimilar Pathogens 
Nrampl's sequence reveals a highly hydrophobic protein 
that could thread through a membrane 12 times with its 
N-terminus in the cytoplasm and N-linked sugars out (Vidal 
et al., 1995; Gruenheid et al., 1995). Twenty inbred mouse 
strains resistant to BCG carried Gly at what was called 
position 105 within the second putative transmembrane 
domain (Malo et al., 1994); this is now considered position 
169 within the fourth transmembrane domain (Vidal et al., 
1995). The change in numerology reflects the recognition 
of an unspliced intron in the originally reported cDNA (Vi- 
dal et al., 1993), whose absence from subsequently cloned 
cDNAs restored 64 amino acid residues to the N-terminus 
(Barton et al., 1994; Cellier et al., 1994). In contrast, seven 
BCG-sensitive strains bore Asp-169, a potentially disrup- 
tive mutation (Vidal et al., 1993; Malo et al., 1994). Nucleo- 
tide differences in NRAMP1 coding regions from 27 strains 
of mice were otherwise silent. Gly-169 was conserved in 
human, rat, and chicken and is considered wild type (Malo 
et al., 1994). Homozygous NRAMPl-deficient mice were 
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precisely as susceptible to pathogens as were homozy- 
gous NRAMP1-Asp-169 mice. Thus, G169D is a null allele 
of NRAMP1 (Vidal et al., 1995). 
At the cDNA level, human NRAMP1, which maps to chro- 
mosome 2q35, is 86%-88% identical to that in mouse 
(Cellier et al., 1994; Blackwell et al., 1995). Of the 12 pre- 
dicted transmembrane domains, 10 are totally conserved, 
despite the expectation that substitution of hydrophobic 
residues would be tolerated. In particular, the Gly that un- 
derwent mutation to Asp in susceptible mice was con- 
served both in the human cDNA studied by Cellier et al. 
(1994) and in all 19 individuals tudied by Blackwell et al. 
(1995). The conservation extends to the atypical intra- 
membranous residues with charged side chains, an evolu- 
tionary highlight suggesting that transport of a charged 
species may be central to the function of Nrampl. 
Recent identification of Nramp family members in more 
distant species revealed zealously conserved features 
that endorse the notion that these proteins serve to trans- 
port ions (Cellier et al., 1995). Homologs in yeast, rice, and 
fly are 28%, 40%, and 55% identical to mouse Nrampl 
(Cellier et al., 1995). Homology is particularly striking in the 
first to third and eighth to tenth putative transmembrane 
regions and in the transport signature between transmem- 
brane domains 8 and 9 (Cellier et al., 1995). In 6 of the 10 
transmembrane segments, a charged residue is invariant. 
The residue corresponding to Gly-169 of mouse Nrampl 
is conserved in all other animal species tested (human, 
rat, chicken, and fly) (Cellier et al., 1995). The function of 
these Nrampl homologs is not yet known. 
A family of several NRAMPl-related genes is said to be 
extensively conserved in rodents and humans (Cellier 
et al., 1994; Vidal et al., 1995). Mouse NRAMP2 cDNA 
has been cloned and its mRNA detected in many tissues 
(Gruenheid et al., 1995). No evidence implicates the 
NRAMPl-related mammalian genes in host resistance. 
Cytokines and Microbial Products May 
Regulate NRAMP1 
If you were the engineer, in what cells would you express 
a natural resistance gene and how would you regulate it? 
The strategy for identification of mouse Nrampl included 
screening for candidate cDNAs that were restricted to 
macrophages and constitutively expressed. Ironically, it 
is not clear that Nrampl does or should meet either crite- 
rion. To begin, the cDNA came from a pre-B cell library 
(Vidal et al., 1993). Subsequent analysis of NRAMPI's 5'- 
flanking region (Govoni et al. 1995) revealed no TATA or 
CAAT sequences typical of inducible genes, but nonethe- 
less divulged multiple y-interferon (IFNy) response ele- 
ments, IFN-stimulated response elements/IFNy-activating 
sequences, and NF-IL6-binding sites. The 5'-flanking re- 
gion of human NRAMP1 likewise contained multiple IFNy 
response elements as well as NF-KB sites typical of induc- 
ible genes (Blackwell et al., 1995). Indeed, IFNy and bacte- 
rial lipopolysaccharides markedly augmented the consti- 
tutively expressed NRAMP1 mRNA in a macrophage-like 
cell line (Govoni et al., 1995). IFNy and granulocyte-mac- 
rophage colony-stimulating factor induced apparently de 
novo expression of NRAMP1 mRNA in primary mouse 
splenic macrophages (Brown et al., 1995), even though 
other investigators found NRAMP1 mRNA constitutively 
in spleen and presumed that macrophages were the cells 
expressing it (Vidal et al., 1993, 1995). Such lab-to-lab 
differences are commonplace in the study of macro- 
phages, perhaps the cells most finely poised to sense envi- 
ronmental signals, even those inapparent o the investiga- 
tor. Up-regulation of Nrampl in response to infection or 
inflammation could be rationalized if Nrampl's antimicro- 
bial effectiveness were maximized in concert with other 
host cell processes subject to similar regulation, such as 
acidification of phagosomes and generation of reactive 
oxygen intermediates. 
Nrampl and NO 
Vidal et al. (1993) noted primary sequence homology be- 
tween a 20 residue region of NRAMP1 separating trans- 
membrane domains 8 and 9 and a motif contributing to 
the interaction of bacterial periplasmic permeases with 
ATP-binding proteins. The motif is shared by over 50 pro- 
teins, most of them believed to be involved in transmem- 
brane carriage (Gruenheid et al., 1995), including a nitrate 
transporter from aspergillus. The latter resemblance 
spurred Vidal et al. (1993) to hypothesize that Nrampl 
functions by transporting nitrite from one intracellular com- 
partment, such as cytosol, to a more acidic one, such as 
phagolysosomes, to be converted therein to NO. 
That NO or one of its reaction products has antimicrobial 
actions is on solid experimental footing. NO synthase type 
2 (the inducible isoform, iNOS) is often expressed or sup- 
pressed coordinately with antimicrobial activity (e.g., Sten- 
ger et al., 1994). Inhibitors of iNOS often block antimicro- 
bial or antiviral activity in vitro, and in vivo such agents 
can block the resolution of infections, resulting in lethality 
(reviewed by De Groote and Fang, 1995). Transfection of 
cells with iNOS cDNA or organochemical provision of NO 
can confer resistance to infectious agents (e.g., Karupiah 
et al., 1993). Doubts raised by NO's lack of antimicrobial 
effect against some pathogens when tested alone may be 
assuaged by recent evidence of synergism with other host 
molecules. Thus, in the experiments of Pacelli et al. (1995), 
neither NO nor H202 was bacteriocidal, but together they 
killed four logs of Escherichia coli. Similarly, NO alone 
was nonbacteriostatic, but its adduct with glutathione re- 
stricted proliferation of S. typhimurium, and its reaction 
products with 02- were bacteriocidal (De Groote et al., 
1995). Finally, mice rendered genetically deficient in iNOS 
through homologous recombination (MacMicking et al., 
1995) or unspecified rearrangement (Wei et al., 1995) are 
less able than wild type to control some infections. 
However, matters are complicated by NO's high reactiv- 
ity and short half-life. In aqueous media, NO combines 
with oxygen to yield higher oxides whose accumulating 
endproducts are nitrite and nitrate. Mammalian systems 
are not known to reduce nitrate. However, at pH -4 .5 -  
5.5, lysosomes or phagolysosomes may protonate a signif- 
icant amount of nitrite to nitrous acid (pKa 3.4). Nitrous 
acid can dismutate to give rise to NO. This prompted 
Stuehr and Nathan (1989) to propose that biologically non- 
reactive nitrite may shuttle NO equivalents through NO- 
scavenging environments into acidic compartments (intra- 
cellular or extracellular) to regenerate NO. 
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An extension of the transport argument envisions 
Nrampl pumping nitrite from the extracellular fluid into 
cells, including cells that fail to produce NO biosyntheti- 
cally. This proposal is inspired by the observation that cells 
expressing iNOS, constituting a small percentage of a 
population of transiently transfected cells, suppressed 
replication of viruses not only in themselves but also in 
their iNOS-negative neighbors (Karupiah et al., 1993). The 
heterogeneity of iNOS expression in the transiently trans- 
fected population mirrors that in cell populations in which 
iNOS is naturally induced by submaximal stimuli. Thus, 
the transcellular anti-infectious action of NO may be physi- 
ologically important, as are the transcellular actions of NO 
in neurotransmission and regulation of vascular tone. How 
can cells share cytotoxic amounts of NO? Some NO may 
survive the diffusional gauntlet of facile reactions with oxy- 
gen, superoxide, sulfhydryls, and metals (Lancaster, 1994). 
Alternatively, some NO otherwise wasted by reaction with 
oxygen during its extracellular race could be recouped by 
importing nitrite and allowing it to equilibrate with acid 
compartments. The NO arising therein could react with 
intraphagolysosomal pathogens, either directly or con- 
jointly with superoxide by forming peroxynitrite or its prod- 
ucts. Given its lipid solubility, NO could diffuse back from 
acidic vacuoles into the cytosol to confront other patho- 
gens, such as viruses. In sum, a cell population equipped 
to expend energy to scavenge nitrite from the medium 
might achieve more uniformly elevated intracellular NO 
concentrations than one that cannot. Tests of Nrampl's 
putative transport functions are awaited. 
A Wider View of Nrampl's Actions 
Barton et al, (1994) noted that the proline content of 
Nrampl's N-terminal region gave it the look of an SH3- 
binding domain and postulated interactions with tyrosine 
kinases or cytoskeletal elements. However, such interac- 
tions have not been demonstrated, nor would they neces- 
sarily narrow the field for possible functions of Nrampl. 
The prolines are not conserved in Nramp's homologs (Cel- 
lier et al., 1995). Blackwell et al. (1994) recognized that 
Nrampl exhibits 30% identity over its whole sequence 
with two similarly sized yeast proteins, SmfF1 and Smf2. 
The role of the latter in mitochondrial protein import 
prompted the suggestion that Nrampl in endosomal or 
phagolysosomal membranes might help load antigenic 
peptides onto major histocompatibility complex class II 
molecules (Blackwell et al., 1994). However, the contribu- 
tion of Smfl and Smf2 to protein import may be indirect 
(Cellier et al., 1995), and peptides loaded on class II are 
believed to be generated intralumenally, not translocated. 
Blackwell et al. (1994) further proposed that Nrampl may 
transport L-arginine to enhance the production of NO. 
However, characterized transporters appear to account 
for both basal and immunologically stimulated uptake of 
L-arginine (Cunningham et al., 1995). 
An apparent challenge to the nitrite transport hypothesis 
for Nrampl's function is the pleiotypy of differences be- 
tween macrophages from mice bearing resistant and sus- 
ceptible alleles of NRAMPI. As reviewed by Barton et al. 
(1995), wild-type NRAMP1 confers modest increases in 
microbe- or cytokine-enhanced expression of tumor necro- 
sis factor, iNOS, the KC chemokine, major histocompati- 
blity complex class II antigens, the respiratory burst, and 
L-arginine uptake. Thus, Nrampl would appear to affect 
some early step in macrophage activation. Synergistic in- 
teractions have been invoked to explain how small incre- 
ments in the foregoing phenotypes could lead to multilog 
differences in microbial burden (Barton et al., 1995). 
To test the activation hypothesis, Barton et al. (1995) 
undertook experiments to analyze the mechanism of ac- 
tion of Nrampl. They transfected NRAMP1 cDNA into the 
RAW 264.7 cell line, whose own NRAMP1 is homozygous 
susceptible (Asp-169/Asp-169), and assayed stably ex- 
pressing clones for their respiratory burst, nitrite produc- 
tion, and L-arginine uptake. Small increases in all three 
assays were seen in some clones. It was not indicated 
whether the variability correlated with differences in levels 
of wild-type Nrampl and whether the cells transfected with 
control vector (NRAMP1-Gly-169) expressed comparable 
amounts. Unfortunately, enhanced antimicrobial activity-- 
the cardinal feature of Nrampl --went untested, perhaps 
because transfectable macrophage cell lines replicate too 
fast to permit meaningful evaluation of antimycobacterial 
or antileishmanial ctivity, while fully differentiated macro- 
phages are notoriously difficult to transfect. 
NO's Unpaired Electron: A Key To Many Locks? 
NO may be the smallest, least charged, most water- and 
lipid-soluble carrier available in biological systems for 
chaperoning a free electron within and between cells. 
These properties give NO access to the interiors of macro- 
molecules and the ability to alter active sites. For example, 
NO can regulate ion channels (Dong et al., 1995), tyrosine 
kinases and phosphatases (Stamler, 1994), GTPases 
(Lander et al., 1995), and transcription factors (Stamler, 
1994). If Nrampl acts primarily to enhance NO concentra- 
tions in a cell population containing point sources of NO, 
this could regulate multiple facets of cell activation or dif- 
ferentiation, just as NO production in response to nerve 
growth factor was implicated in the differentiation of neu- 
rons (Peunova and Enikolopov, 1995). The same argu- 
ment for pleiotropic effects could apply if Nrampl proves 
to transport ions other than or in addition to nitrite. 
Many unanswered questions are raised here. Which 
cells express Nrampl? Where in the cell does it reside? 
How is it regulated transcriptionally and posttranscription- 
ally? What ions does it carry? These should not distract 
us from other equally important questions. Do NRAMPI's 
alleles control susceptibility and resistance of human pop- 
ulations to infectious disease? What other allelic systems 
control innate resistance? How do human macrophages 
kill pathogens? 
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